103 TCOG102 11 01

*103

103

103 *

99 500

*

103 3 1 103 3 31

https://pfp.hpa.gov.tw 4 8 *

*

10356610

*

900 2 50% *

*

30 5 5 30 5 12301320300 40 20

*

*

4 (1 )1 6 1 17 6 6 1 2 1 1 36 10 2

*2.24.4

1.11.21.31.42.12.22.32.42.52.63.13.23.3.13.3.23.3.33.3.43.43.53.6.13.6.23.7.13.7.23.83.93.6.33.6.43.104.14.24.34.44.54.65.15.26.1

*

Rating A 10 Rating A + Rating B 26 Rating D + Rating E 0 10 Rating B 5 Rating A Rating A + Rating B > 10 Rating D 3 Rating E 0 Rating A + Rating B 10 Rating D 4 Rating E 1

B

1.22.43.23.3.33.53.6.23.6.33.104.15.1*

*

4 991001110312311031 102 103111031231103 2 101102103

*

102 1 102 12 101 1 102 12 102 1 103 2 103 2

-1 2

(*

-2

*

103*

*

*

1.1Rating ERating DRating C50%

*

1.1Rating B C Rating A B 1.2 75 %

*

1.1

*

1.1

*

*

*

1.2 1234

*

1.2 Rating ERating D Rating C Rating CRating B C

*

1.2 Rating A B 14

*

1.2

)*

*

-1

*3.13.23.6.13.7.23.83.91.1

-2

*

1.3 Rating ERating D Rating C Rating CRating B CPDCARating A BPDCA

*

1.312

*

99

125 *

*

1.4 1AJCC 23

4

*

1.4 1AJCC23

*

1.4

*

*

*

9811 6 2.1 D

22.1 D*

*

2.1Rating E Rating D Rating DRating CRating B C

*

2.1Rating A B 3,000 1 3,000 2 102 1

*

2.120

*

2.1103100

*

*

2.2Rating E Rating D Rating D95%98%90%95%Rating C98%95%98%Rating B98%98%95%Rating A98%

*

2.299101101101(1) ( A / B ) 100%101A99 B99 + 99

*

2.2(2) ( E+F ) / D 100% (101)D99E9999F9999

*

2.2(3) ( G / H ) 100% (101)G99H99

2.

*

2.3Rating ERating D Rating C Rating CRating B C Rating A B

*

2.3

*

2.3Rating A 3 123

*

1.3 2.3

*

*

2.4 Rating ERating D Rating C Rating CRating B CRating A B

*

2.4 1 2 3 4Class1~2 5

*

2.4 2.5

*

*

2.5Class1~2Rating E

Rating D Rating C

Rating C 80%

*

2.5Rating B C 80 ~ 95%

Rating A B 95%

*

2.5Class 1~ 2Stage

*

2.5123 Class 1~245

*

2.5K / L 100 % K L

10% Class 1~2

*

96 2.13Tumor Size96983.4 T Clinical T1151172.14Regional Lymph Nodes Examined991003.5 N Clinical N1181192.15Regional Lymph Nodes Positive1011023.6 M Clinical M1201213.7Clinical Stage Group122124

*

3.10 T Pathologic T127129Other Staging System FIGO3.11 N Pathologic N130131Other Staging SystemBCLC1013.12 M Pathologic M1321333.13Pathologic Stage Group134136Other Staging Systemhistology101

2.4

*

-1 1.5

coding*

-2 99 1 1 AJCC 7 AJCC 7

103102101 *

*

2.6 Class 03Rating ERating DRating CRating B CRating A B

*

2.61 Class 0~32 Class 1~2 2 5 Class 0 3 3456

*

2*

*

*

3.1Rating ERating D Rating C Rating CRating B C

*

3.1Rating A B /

*

3.11 peer review article234

*

3.1Rating A Hodgkin lymphomaBDiffuse large B cell lymphoma Follicular lymphoma

*

-11. work-up 2. 90R/T C/T3. *

-2 6 1~3 10 3*

4123

*

3.2 Rating ERating D Rating C Rating C70 %Rating B C50%

*

3.2 Rating A BClass 1~2

*

3.2 Class 1~21 2 2

3

1,000 61,001~2,00092,001 12

*

3.2 123minimum requirement12345comorbidity6regimensdose

*

3.2 C B summary note

*regimenR/Tdose

-1

*

-2 toxicity *

-3

*

*

3.3 3.3.1 Rating E 20 %Rating D20 % 40 %Rating C40 % 60 %Rating B60 % 80 %Rating A 80 %

*

3.3.112TNM AJCC

*

3.3.1

12 7 2 4 1 1 [ ( 27 + 14 + 01 ) / ( 212 ) ] 100 %18 / 24 100 %75 %Rating B3.2

*

TNM

Initial staging*

*

3.3.2 Rating E 20 %Rating D20 % 40 %Rating C40 % 60 %Rating B60 % 80 %Rating A 80 %

*

3.3.2123

*

3.3.2

12 8 3 3 2 1 1 [ ( 38 + 23 + 11 ) / ( 312 ) ] 100 %31 / 36 100 %86 %Rating A3.2

*

Toxicity survey sheet

*

*

3.3.3 Rating E 20 %Rating D20 % 40 %Rating C40 % 60 %Rating B60 % 80 %Rating A 80 %

*

3.3.3 123Neoadjuvant

*

3.3.3

9 4 3 2 2 2 1 1 [ ( 34 + 22 + 12 + 01 ) / ( 39 ) ] 100 %18 / 27 100 %67 % Rating B 3.2

*1.

*

*

3.3.4Rating E 20 %Rating D20 % 40 %Rating C40 % 60 %Rating B60 % 80 %Rating A 80 % curative intent

*

3.3.4curative intent123 1 13 C

*

3.3.4

9 2 3 3 2 3 1 1 [ ( 32 + 23 + 13 + 01 ) / ( 39 ) ] 100 %15 / 27 100 %56 % Rating C3.2

*

progress note

*

*

3.4Rating ERating D Rating C Rating CRating B C70 %

*

3.4Rating A B

*

3.4

*

3.424 B1502

*

1. 2. 3. 4. 5. 6. ()

*

7. 8. 9. 10. 11. 12.

*

-1

*

-250*

*

3.5 Rating ERating D Rating C Rating C10%

*

3.5 Rating B C10%5%Rating A B10%20%10%

*

3.5 Class 1~3

*

3.5 12 30 3123

*

3.5 1234

*

3.5 1conclusion or recommendation 2process

* 10%

50%

*

*

3.63.6.1Rating ERating D Rating C Rating C

*

3.6.1Rating B C

Rating A B

*

3.6.1AdjuvantNeoadjuvantConcurrent Chemoradiotherapy, CCRT

*

3.6.11 peer review article234

*

AdjuvantNeoadjuvantCCRT*

*

3.6.2 Rating ERating DRating CRating C 3.6.1 prescriptionRating B CprescriptionRating A B

*

3.6.2 1.prescription

*

regimen *

*

3.6.3 Rating ERating D Rating C Rating CRating B CRating A B

*

3.6.3

*

3.6.3 123

*

3.6.3

*

3.6.3 ( spill kits ) 1

Class II BClass III

*

3.6.3 2

*

A B

*

*

3.6.4 Rating ERating D Rating C Rating CRating B CRating A B

*

3.6.412

*

3.6.4

*

3.6.43.6.3

*

*

*

3.73.7.1Rating ERating D Rating C Rating C

*

3.7.1Rating B CRating A B

*

3.7.112 permanent sectionHer-2 / neu CAPTAF

*

*

*

3.7.2Rating ERating D Rating C Rating CRating B C

*

3.7.2Rating A B

*

*

*

3.8 Rating E Rating D Rating C Rating CRating B C

*

3.8Rating A B

*

3.8 CT MRI

*

*

*

3.9Rating ERating D Rating C Rating Ccurative intent Rating B CRating C curative intent

*

3.9Rating A BRating C curative intent

*

3.9 12CTVPTV

*

3.91peer review article234

*

3.912CCE

*

*

*

3.10 Rating ERating D Rating C Rating CRating BRating A

*

3.10 103

*

*

*

4.1 123 / 4Rating E

Rating DRating C

*

4.1 Rating CRating B CRating A B

*

4.1 / Port - AHickmanPICC /

*

4.1 3.6.4

*

QCCRCAPDCA -1*

-2

*

*

4.2 Rating E Rating D Rating C Rating C Rating B C Rating A B

*

4.23.6.4

*

*

*

4.3 Rating ERating D Rating C Rating CRating BRating A

*

4.3

*

4.31.3341 3.6.4

*

QCCRCAFMEA PDCA PDCA PDCA PDCA 2

100%*

*

4.4Rating E Rating D Rating C Rating C

*

4.4Rating B C208020Rating A B 6 50%

*

4.4 20

*

4.4666

*

8 50%

progress note

*

*

4.5Rating ERating D Rating C Rating C 50 Rating B C Class1~2 400

*

4.5Rating A B 103100

*

4.51 1 2 234 C

*

2

100103*

*

4.6 Rating ERating D Rating C Rating CRating B C

*

4.6Rating A B

*

4.6

*

4.6

A intake BMI

*

Rating B A Rating B Rating A 4 *

*

*

5.1 Rating ERating D Rating C Rating CRating B CRating A B

*

5.1 2 PDCA

2

*

*

5.2 Rating ERating DRating CRating B CRating A B

*

5.2

*

*

*

6.1 Class1~2 2,000 A IRB Class1~2 2,000 1 A

*

6.1 IRB

*

*